Sensodyne shines for GSK but Lucozade is off-colour
Toothpaste and smoking quitting aids helped drive growth at the consumer healthcare arm of GlaxoSmithKline over the past three months.
Sales in the consumer healthcare division were up 5% in the past three months to £1.33bn, driven by strong growth for the oral healthcare business, up 10%, and the Sensodyne brand in particular.
Nutritional healthcare was up 9% thanks to the Maxinutrition acquisition earlier this year, while sales of Lucozade took a hit from increased activity by rival brands.
Sales of over-the-counter medicines, where GSK owns brands including Beechams, Gaviscon and Nytol, were flat for the period.
Meanwhile, GSK warned that the impact of forced price cuts on pharmaceuticals in Europe and the US could cost it as much as £325m for the full year. Sales across the business, including its pharmaceutical and vaccines divisions, were up 4% for the three-month period to £7.1bn.